StudyFinder
MT2015-25: Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
Status: Recruiting
The primary purpose of this study is to gain information, especially disease free outcomes, using the tandem approach as compared to the historical information of using a single transplant. The data will be analyzed for transplant “milestones” such as time to blood count recovery and how patients are doing at 3 months and 1 year after the treatment. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.
Sex: Male or Female
Age Group: Not specified
Inclusion Criteria:
• less than 30 years old when diagnosis of neuroblastoma is made
• no uncontrolled infection
• recovered from acute toxicities of last cycle of induction chemotherapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Conditions:
Cancer
Keywords:
Neuroblastoma
Study Contact: Holly Franceen - hfrancee@umn.edu
Principal Investigator: Ashish Gupta
Phase: PHASE2
IRB Number: 1601M82901
See this study on ClinicalTrials.gov